Results 31 to 40 of about 10,319 (186)

Structure and antagonism of the receptor complex mediated by human TSLP in allergy and asthma

open access: yesNature Communications, 2017
The pro-inflammatory cytokine thymic stromal lymphopoietin (TSLP) is a promising therapeutic target. Here the authors characterize the assembly mechanism of the receptor complex driven by human TSLP, and its antagonism by the monoclonal antibody ...
Kenneth Verstraete   +14 more
doaj   +1 more source

The Role of Thymic Stromal Lymphopoietin (TSLP) in Glomerulonephritis [PDF]

open access: yesChildhood Kidney Diseases, 2018
Thymic stromal lymphopoietin (TSLP) is an interleukin-7-like cytokine that is an important trigger and initiator of many allergic diseases. TSLP promotes a T-helper type 2 (Th2) cytokine response that can be pathological. A relationship is formed both at
Keum Hwa Lee   +8 more
doaj   +1 more source

Leptin May Promote Eosinophilic CRSwNP Progression by Enhancing Eosinophil Chemotaxis and Angiogenesis Under a Type 2 Inflammatory Milieu

open access: yesInternational Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Chronic rhinosinusitis with nasal polyp (CRSwNP) is a heterogeneous Type 2 inflammatory disease characterized by enhanced eosinophilic infiltration. Both innate and adaptive immunity are involved in the onset and progression of CRSwNP.
Yuki Sonoda   +4 more
wiley   +1 more source

Thymic Stromal Lymphopoietin and Cancer: Th2-Dependent and -Independent Mechanisms

open access: yesFrontiers in Immunology, 2020
The thymic stromal lymphopoietin (TSLP) is an IL-7-like cytokine originally cloned from a murine thymic stromal cell line, and subsequently a human homolog was identified using database search methods.
Maria Pia Protti   +3 more
doaj   +1 more source

The Role of TSLP in Atopic Dermatitis: From Pathogenetic Molecule to Therapeutical Target

open access: yesMediators of Inflammation, 2023
Atopic dermatitis (AD) is a kind of chronic skin disease with inflammatory infiltration, characterized by skin barrier dysfunction, immune response dysregulation, and skin dysbiosis.
Jialiang Luo   +9 more
doaj   +1 more source

Tezepelumab in Chinese Patients With Severe Chronic Rhinosinusitis With Nasal Polyps: A Prespecified Subgroup Analysis of the Phase 3 WAYPOINT Trial

open access: yesInternational Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Chronic rhinosinusitis with nasal polyps (CRSwNP) in Chinese patients often exhibits a mixed Type 1/2/3 inflammatory phenotype (63%), potentially impacting the efficacy of biologics targeting Type 2 inflammation. This prespecified subgroup analysis of WAYPOINT (NCT04851964) evaluated the efficacy and safety of tezepelumab in Chinese
Li Hu   +9 more
wiley   +1 more source

Molecular Targets for Biological Therapies of Severe Asthma: Focus on Benralizumab and Tezepelumab

open access: yesLife, 2021
Asthma is a heterogeneous respiratory disease characterized by usually reversible bronchial obstruction, which is clinically expressed by different phenotypes driven by complex pathobiological mechanisms (endotypes).
Shih-Lung Cheng
doaj   +1 more source

Chronic Rhinosinusitis and Nasal Polyps in Eosinophilic Granulomatosis With Polyangiitis: A Scoping Review

open access: yesInternational Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Chronic rhinosinusitis (CRS) is one of the most common manifestations of eosinophilic granulomatosis with polyangiitis (EGPA), often preceding the diagnosis of systemic vasculitis by several years. The sinonasal presentation of EGPA typically resembles CRS with nasal polyps (CRSwNP), making it clinically indistinguishable from those
Alisha Sharma   +12 more
wiley   +1 more source

Tezepelumab achieves improvement of severe uncontrolled asthma and rhinosinusitis: Case series

open access: yesJournal of Allergy and Clinical Immunology: Global
Tezepelumab, a mAb targeting thymic stromal lymphopoietin (TSLP), reduces exacerbations in severe asthma. Four cases in which patients with severe asthma and chronic rhinosinusitis with nasal polyps showed improvements in both conditions after receiving ...
Shigesato Inoue, MD   +8 more
doaj   +1 more source

Pharmacokinetics and safety of tezepelumab in children with mild, moderate or severe asthma and adolescents with mild‐to‐moderate asthma

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Tezepelumab is a human monoclonal antibody that blocks the activity of thymic stromal lymphopoietin and is approved for adolescents and adults with severe asthma. This analysis assessed pharmacokinetics (PK), pharmacodynamics and safety of tezepelumab up to 85 days postdose in adolescents and children.
Anna Lundahl   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy